Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 3 (2006), Issue 2 (February)

1. Massive pulmonary embolism.
   Circulation, 113(4): 577-82. [Abstract] [Full-text]
2. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis.
   Lancet, 367(9508): 404-11. [Abstract] [Full-text]
3. Sclerosing therapy as first line treatment for low flow vascular lesions of the orbit.
   Am J Ophthalmol, 141(2): 333-9. [Abstract] [Full-text]
4. Modeling, identification and nonlinear model predictive control of type I diabetic patient.
   Med Eng Phys, 28(3): 240-50. [Abstract] [Full-text]
5. Capecitabine plus weekly oxaliplatin in gastrointestinal tumors: a phase I study.
   Am J Clin Oncol, 29(1): 85-9. [Abstract] [Full-text]
6. Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients.
   Am J Clin Oncol, 29(1): 45-51. [Abstract] [Full-text]
7. The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer.
   Am J Clin Oncol, 29(1): 40-4. [Abstract] [Full-text]
8. A phase I dose finding study of cisplatin, gemcitabine, and weekly docetaxel for patients with advanced transitional cell cancer.
   Am J Clin Oncol, 29(1): 3-7. [Abstract] [Full-text]
9. Fluid resuscitation in liposuction: a retrospective review of 89 consecutive patients.
   Plast Reconstr Surg, 117(2): 431-5. [Abstract] [Full-text]
10. Resuscitation fluid volume and abdominal compartment syndrome in patients with major burns.
    Burns, 32(2): 151-4. [Abstract] [Full-text]
11. Cyclodextrin-grafted polysaccharides as supramolecular carrier systems for naproxen.
    Bioorg Med Chem Lett, 16(6): 1499-501. [Abstract] [Full-text]
12. Adenoviral modification of mouse brain derived endothelial cells, bEnd3, to induce apoptosis by vascular endothelial growth factor.
    Oncogene, 25(6): 954-8. [Abstract] [Full-text]
13. New cyclodextrin hydrogels cross-linked with diglycidylethers with a high drug loading and controlled release ability.
    Pharm Res, 23(1): 121-30. [Abstract] [Full-text]
14. Varying the unsaturation in N4,N9-dioctadecanoyl spermines: nonviral lipopolyamine vectors for more efficient plasmid DNA formulation.
    Pharm Res, 23(1): 31-40. [Abstract] [Full-text]
15. Case reports of suspected adverse drug reactions--systematic literature survey of follow-up.
    BMJ, 332(7537): 335-9. [Abstract] [Full-text]
16. Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma.
    J Clin Oncol, 24(5): 748-54. [Abstract] [Full-text]
17. Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells.
    AIDS, 20(4): 627-30. [Abstract] [Full-text]
18. The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy.
    AIDS, 20(4): 619-21. [Abstract] [Full-text]
19. Effect of hepatitis C coinfection on discontinuation and modification of initial HAART in primary HIV care.
    AIDS, 20(4): 575-83. [Abstract] [Full-text]
20. Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality.
    AIDS, 20(4): 561-5. [Abstract] [Full-text]
21. Viral dynamics after starting first-line HAART in HIV-1-infected children.
    AIDS, 20(4): 517-23. [Abstract] [Full-text]
22. Towards developing surface eroding poly(alpha-hydroxy acids).
    Biomaterials, 27(15): 3021-30. [Abstract] [Full-text]
23. Sustained release of dexamethasone from hydrophilic matrices using PLGA nanoparticles for neural drug delivery.
    Biomaterials, 27(15): 3031-7. [Abstract] [Full-text]
24. Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients.
    Cancer Chemother Pharmacol, 57(5): 615-23. [Abstract] [Full-text]
25. A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors.
    Cancer Chemother Pharmacol, 57(5): 671-7. [Abstract] [Full-text]
26. The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer.
    Cancer Chemother Pharmacol, 57(5): 577-83. [Abstract] [Full-text]
27. Failure of neutrophil chemotactic function in breast cancer patients treated with chemotherapy.
    Cancer Chemother Pharmacol, 57(5): 663-70. [Abstract] [Full-text]
28. Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: results from a pilot trial.
    Cancer Chemother Pharmacol, 57(5): 554-8. [Abstract] [Full-text]
29. Phase I/II dose escalation study of angiotensin 1-7 [A(1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer.
    Cancer Chemother Pharmacol, 57(5): 559-68. [Abstract] [Full-text]
30. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia.
    J Natl Cancer Inst, 98(4): 273-84. [Abstract] [Full-text]
31. Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir.
    J Natl Cancer Inst, 98(4): 236-44. [Abstract] [Full-text]
32. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
    Cancer Chemother Pharmacol, 57(5): 693-702. [Abstract] [Full-text]
33. High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline- and taxane-pretreated metastatic breast cancer.
    Cancer Chemother Pharmacol, 57(5): 640-6. [Abstract] [Full-text]
34. PDT as a cytotoxic agent and biological response modifier: Implications for cancer prevention and treatment in immunosuppressed and immunocompetent patients.
    J Invest Dermatol, 126(3): 542-4. [Abstract] [Full-text]
35. Photodynamic therapy does not prevent cutaneous squamous-cell carcinoma in organ-transplant recipients: results of a randomized-controlled trial.
    J Invest Dermatol, 126(3): 569-74. [Abstract] [Full-text]
36. Relationship between cisplatin administration and the development of ototoxicity.
    J Clin Oncol, 24(6): 918-24. [Abstract] [Full-text]
37. Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000.
    J Clin Oncol, 24(6): 872-7. [Abstract] [Full-text]
38. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
    J Clin Oncol, 24(6): 929-36. [Abstract] [Full-text]
39. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs.
    J Clin Oncol, 24(6): 953-60. [Abstract] [Full-text]
40. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
    J Clin Oncol, 24(6): 937-44. [Abstract] [Full-text]
41. Perfusion CT helps decision making for thrombolysis when there is no clear time of onset.
    J Neurol Neurosurg Psychiatry, 77(3): 417-9. [Abstract] [Full-text]
42. Headache and migraine in primary care: consultation, prescription, and referral rates in a large population.
    J Neurol Neurosurg Psychiatry, 77(3): 385-7. [Abstract] [Full-text]
43. Thrombolysis for acute stroke with special emphasis on the very old: experience from a single Dutch centre.
    J Neurol Neurosurg Psychiatry, 77(3): 375-7. [Abstract] [Full-text]
44. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study.
    Br J Ophthalmol, 90(3): 337-41. [Abstract] [Full-text]
45. Correlation of optical coherence tomography and fundus fluorescein angiography following photodynamic therapy for choroidal neovascular membranes.
    Br J Ophthalmol, 90(3): 304-6. [Abstract] [Full-text]
46. Topical photodynamic therapy for primary cutaneous B-cell lymphoma: a pilot study.
    J Am Acad Dermatol, 54(3): 524-6. [Abstract] [Full-text]
47. CD127 expression and regulation are altered in the memory CD8 T cells of HIV-infected patients--reversal by highly active anti-retroviral therapy (HAART).
    Clin Exp Immunol, 143(3): 398-403. [Abstract] [Full-text]
48. Back pain after photodynamic therapy with verteporfin.
    Am J Ophthalmol, 141(3): 593-4. [Abstract] [Full-text]
49. Early optical coherence tomography changes after photodynamic therapy in patients with age-related macular degeneration.
    Am J Ophthalmol, 141(3): 574-6. [Abstract] [Full-text]
50. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy.
    Am J Epidemiol, 163(5): 412-20. [Abstract] [Full-text]
51. Effect of a closed drug-delivery system on the incidence of nosocomial and catheter-related bloodstream infections in infants.
    Epidemiol Infect, 134(2): 285-91. [Abstract] [Full-text]
52. Non-anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged 60 or older.
    Leuk Res, 30(4): 503-6. [Abstract] [Full-text]
53. Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia.
    Leuk Res, 30(4): 407-13. [Abstract] [Full-text]
54. The effect of the Hyper-CVAD chemotherapy regimen on fertility and ovarian function.
    Leuk Res, 30(4): 483-5. [Abstract] [Full-text]
55. Isotonic is better than hypotonic saline for intravenous rehydration of children with gastroenteritis: a prospective randomised study.
    Arch Dis Child, 91(3): 226-32. [Abstract] [Full-text]
56. Intrathecal catheter granuloma associated with isolated baclofen infusion.
    Anesth Analg, 102(3): 848-52. [Abstract] [Full-text]
57. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer.
    Br J Cancer, 94(4): 524-31. [Abstract] [Full-text]
58. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study.
    Br J Cancer, 94(4): 481-5. [Abstract] [Full-text]
59. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission.
    Blood, 107(5): 2184-91. [Abstract] [Full-text]
60. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
    N Engl J Med, 354(8): 809-20. [Abstract] [Full-text]
61. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique.
    Cancer, 106(5): 1144-53. [Abstract] [Full-text]
62. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?
    Cancer, 106(5): 1041-6. [Abstract] [Full-text]
63. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.
    Cancer, 106(5): 1007-16. [Abstract] [Full-text]
64. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy.
    Cancer, 106(5): 1000-6. [Abstract] [Full-text]
65. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
    Cancer, 106(5): 1099-109. [Abstract] [Full-text]
66. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome.
    Cancer, 106(5): 1090-8. [Abstract] [Full-text]
67. Hybrid data capture for monitoring patients on highly active antiretroviral therapy (HAART) in urban Botswana.
    Bull World Health Organ, 84(2): 127-31. [Abstract] [Full-text]
68. Coverage and use of prescription drugs in nursing homes: implications for the medicare modernization act.
    Med Care, 44(3): 243-9. [Abstract] [Full-text]
69. Effect of vitamin E supplementation with and without hormone therapy on circulatory inflammatory markers in postmenopausal women.
    Fertil Steril, 85(3): 667-73. [Abstract] [Full-text]
70. Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival.
    J Clin Oncol, 24(7): 1161-8. [Abstract] [Full-text]
71. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer.
    J Clin Oncol, 24(7): 1145-51. [Abstract] [Full-text]
72. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.
    J Clin Oncol, 24(7): 1127-35. [Abstract] [Full-text]
73. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.
    J Clin Oncol, 24(7): 1072-8. [Abstract] [Full-text]
74. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution.
    J Clin Oncol, 24(7): 1064-71. [Abstract] [Full-text]
75. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer.
    J Clin Oncol, 24(7): 1057-63. [Abstract] [Full-text]
76. PCV chemotherapy for recurrent glioblastoma.
    Neurology, 66(4): 587-9. [Abstract] [Full-text]
77. Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma.
    Expert Rev Anticancer Ther, 6(3): 437-43. [Abstract] [Full-text]
78. Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions.
    Expert Rev Anticancer Ther, 6(3): 427-36. [Abstract] [Full-text]
79. Management of prostate cancer. Part 1: chemoprevention.
    Expert Rev Anticancer Ther, 6(3): 419-25. [Abstract] [Full-text]
80. Future chemotherapy and radiotherapy options in head and neck cancer.
    Expert Rev Anticancer Ther, 6(3): 395-403. [Abstract] [Full-text]
81. Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma.
    Expert Rev Anticancer Ther, 6(3): 383-94. [Abstract] [Full-text]
82. Treatment of Burkitt lymphoma in adults.
    Expert Rev Anticancer Ther, 6(3): 373-81. [Abstract] [Full-text]
83. Treatment of gastric mucosa-associated lymphoid tissue lymphoma: Helicobacter pylori eradication and beyond.
    Expert Rev Anticancer Ther, 6(3): 361-71. [Abstract] [Full-text]
84. Cardiac safety strategies. 25-26 October 2005, the Radisson SAS Hotel, Nice, France.
    Expert Opin Drug Saf, 5(2): 329-33. [Abstract] [Full-text]
85. Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection.
    Expert Opin Drug Saf, 5(2): 275-87. [Abstract] [Full-text]
86. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study.
    J Clin Oncol, 24(7): 1045-51. [Abstract] [Full-text]
87. Role of CT angiography in thrombolysis decision-making for patients with presumed seizure at stroke onset.
    Stroke, 37(3): 915-7. [Abstract] [Full-text]
88. Therapy of basilar artery occlusion: a systematic analysis comparing intra-arterial and intravenous thrombolysis.
    Stroke, 37(3): 922-8. [Abstract] [Full-text]
89. Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients: comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials.
    Stroke, 37(3): 852-8. [Abstract] [Full-text]
90. Hemorrhage in the Interventional Management of Stroke study.
    Stroke, 37(3): 847-51. [Abstract] [Full-text]
91. A pilot study of a new thrombolytic agent for acute ischemic stroke in Taiwan within a five-hour window.
    Stroke, 37(3): 918-9. [Abstract] [Full-text]
92. Pretreatment photosensitizer dosimetry reduces variation in tumor response.
    Int J Radiat Oncol Biol Phys, 64(4): 1211-20. [Abstract] [Full-text]
93. A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results.
    Int J Radiat Oncol Biol Phys, 64(4): 1072-80. [Abstract] [Full-text]
94. Radiation therapy for T2N0 laryngeal cancer: A retrospective analysis for the impact of concurrent chemotherapy on local control.
    Int J Radiat Oncol Biol Phys, 64(4): 995-1001. [Abstract] [Full-text]
95. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC).
    Int J Radiat Oncol Biol Phys, 64(4): 983-94. [Abstract] [Full-text]
96. Supratentorial primitive neuroectodermal tumors (S-PNET) in children: A prospective experience with adjuvant intensive chemotherapy and hyperfractionated accelerated radiotherapy.
    Int J Radiat Oncol Biol Phys, 64(4): 1031-7. [Abstract] [Full-text]
97. Systematic review of systemic therapy for advanced or recurrent endometrial cancer.
    Gynecol Oncol, 101(1): 158-67. [Abstract] [Full-text]
98. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.
    Gynecol Oncol, 101(1): 46-54. [Abstract] [Full-text]
99. Sequential gemcitabine-carboplatin followed by paclitaxel-carboplatin in the first-line treatment of advanced ovarian cancer: A phase II study.
    Gynecol Oncol, 101(1): 114-9. [Abstract] [Full-text]

© 2004-2008 Chemotherapy Research Today. All Rights Reserved.